Obesity is no longer merely a lifestyle-related condition; it's a worldwide epidemic with life-threatening consequences. Satiety is developing a device-based alternative to surgery that could expand the market for both physicians and patients.
by Stephen Levin
While the emergence of so-called quality-of-life (QOL) medicine has had a greater impact in pharmaceuticals, the medical device industry has...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
